AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Novonesis AS

Transaction in Own Shares Mar 7, 2014

3377_dirs_2014-03-07_d3a5cf77-7503-4ae8-99f4-bdc45bc64bdd.pdf

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

March 7, 2014

As of March 6, Novozymes has purchased an accumulated 557,400 shares with a transaction value of DKK 138.8 million under the stock buyback program Novozymes announced in Company announcement No. 17, 2014 and initiated February 17, 2014. Under the program, Novozymes will buy back B shares worth up to DKK 2 billion in total during 2014.

The following transactions have been made under the program in accordance with the provisions of European Commission Regulation (EC) No. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour Regulation:

Number
of shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 349,400 87,084,173
February 28, 2014 39,000 250.83 9,782,475
March 3, 2014 46,000 246.83 11,354,258
March 4, 2014 43,000 248.96 10,705,376
March 5, 2014 40,000 248.18 9,927,281
March 6, 2014 40,000 248.25 9,930,082
Total accumulated under the program 557,400 138,783,645

In addition, transactions necessitated by Novozymes' previously established incentive programs have resulted in a net sale by Novozymes of 13,785 B shares in the period from February 28 to March 6, 2014. The share transactions related to the incentive programs were not part of the Safe Harbour stock buyback program.

Following the transactions stated above, Novozymes owns a total of 4,993,612 treasury shares, corresponding to 1.6% of the stock capital. The total number of shares in the company is 319,700,000, including treasury shares.

Contact information

Investor Relations:
Thomas Bomhoff (DK) +45 3077 1226 [email protected]
Klaus Sindahl (DK) +45 5363 0134 [email protected]
Martin Riise (USA) +1 919 649 2565 [email protected]
Press and media:
Rene Tronborg (DK) +45 3077 2274 [email protected]
Frederik Bjoerndal (Europe) +44 7976 138 265 [email protected]
Paige Donnelly (USA) +1 919 218 4501 [email protected]
Meng Lian (China) +86 136 9923 1164 [email protected]
Henrique Pellini (Brazil) +55 41 9288 0282 [email protected]
Poonam Kapila (India) +91 991 082 2339 [email protected]

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com

Company announcement No. 28, 2014 Page 1 of 1

Talk to a Data Expert

Have a question? We'll get back to you promptly.